149 related articles for article (PubMed ID: 29232562)
1. TM6SF2: A novel target for plasma lipid regulation.
Li TT; Li TH; Peng J; He B; Liu LS; Wei DH; Jiang ZS; Zheng XL; Tang ZH
Atherosclerosis; 2018 Jan; 268():170-176. PubMed ID: 29232562
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice.
Fan Y; Lu H; Guo Y; Zhu T; Garcia-Barrio MT; Jiang Z; Willer CJ; Zhang J; Chen YE
Gastroenterology; 2016 May; 150(5):1208-1218. PubMed ID: 26774178
[TBL] [Abstract][Full Text] [Related]
3. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
[TBL] [Abstract][Full Text] [Related]
4. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.
Mahdessian H; Taxiarchis A; Popov S; Silveira A; Franco-Cereceda A; Hamsten A; Eriksson P; van't Hooft F
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8913-8. PubMed ID: 24927523
[TBL] [Abstract][Full Text] [Related]
5. Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.
Li BT; Sun M; Li YF; Wang JQ; Zhou ZM; Song BL; Luo J
PLoS Genet; 2020 Aug; 16(8):e1008955. PubMed ID: 32776921
[TBL] [Abstract][Full Text] [Related]
6. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.
Ehrhardt N; Doche ME; Chen S; Mao HZ; Walsh MT; Bedoya C; Guindi M; Xiong W; Ignatius Irudayam J; Iqbal J; Fuchs S; French SW; Mahmood Hussain M; Arditi M; Arumugaswami V; Péterfy M
Hum Mol Genet; 2017 Jul; 26(14):2719-2731. PubMed ID: 28449094
[TBL] [Abstract][Full Text] [Related]
7. TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease.
Luo F; Oldoni F; Das A
Hepatol Commun; 2022 Mar; 6(3):448-460. PubMed ID: 34532996
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins.
Smagris E; Gilyard S; BasuRay S; Cohen JC; Hobbs HH
J Biol Chem; 2016 May; 291(20):10659-76. PubMed ID: 27013658
[TBL] [Abstract][Full Text] [Related]
9. Perturbation of
Pant A; Chen Y; Kuppa A; Du X; Halligan BD; Speliotes EK
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575933
[TBL] [Abstract][Full Text] [Related]
10. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
[TBL] [Abstract][Full Text] [Related]
11. Effect of ezetimibe on cholesterol absorption and lipoprotein composition in diabetes and metabolic syndrome.
Federici M
Atheroscler Suppl; 2015 Feb; 17():17-22. PubMed ID: 25659872
[TBL] [Abstract][Full Text] [Related]
12. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis.
Pirola CJ; Sookoian S
Hepatology; 2015 Dec; 62(6):1742-56. PubMed ID: 26331730
[TBL] [Abstract][Full Text] [Related]
13. Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats.
Luo F; Smagris E; Martin SA; Vale G; McDonald JG; Fletcher JA; Burgess SC; Hobbs HH; Cohen JC
Cell Mol Gastroenterol Hepatol; 2022; 13(3):879-899. PubMed ID: 34923175
[TBL] [Abstract][Full Text] [Related]
14. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine.
O'Hare EA; Yang R; Yerges-Armstrong LM; Sreenivasan U; McFarland R; Leitch CC; Wilson MH; Narina S; Gorden A; Ryan KA; Shuldiner AR; Farber SA; Wood GC; Still CD; Gerhard GS; Robishaw JD; Sztalryd C; Zaghloul NA
Hepatology; 2017 May; 65(5):1526-1542. PubMed ID: 28027591
[TBL] [Abstract][Full Text] [Related]
15. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children.
Grandone A; Cozzolino D; Marzuillo P; Cirillo G; Di Sessa A; Ruggiero L; Di Palma MR; Perrone L; Miraglia Del Giudice E
Pediatr Obes; 2016 Apr; 11(2):115-9. PubMed ID: 25893821
[TBL] [Abstract][Full Text] [Related]
16. Nuclear receptors and cholesterol metabolism in the intestine.
Moschetta A
Atheroscler Suppl; 2015 Feb; 17():9-11. PubMed ID: 25659870
[TBL] [Abstract][Full Text] [Related]
17. Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport.
El Khoury P; Waldmann E; Huby T; Gall J; Couvert P; Lacorte JM; Chapman J; Frisdal E; Lesnik P; Parhofer KG; Le Goff W; Guerin M
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):285-94. PubMed ID: 26681758
[TBL] [Abstract][Full Text] [Related]
18. [Research progress of single-nucleotide polymorphism in theTM6SF2 rs58542926].
Li Y; Sun X; Zhan SH; Gao YQ; Xin YN; Xuan SY
Zhonghua Gan Zang Bing Za Zhi; 2019 Mar; 27(3):223-226. PubMed ID: 30929342
[TBL] [Abstract][Full Text] [Related]
19. Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism.
Liu J; Ginsberg HN; Reyes-Soffer G
Curr Opin Lipidol; 2024 Jun; 35(3):157-161. PubMed ID: 38465912
[TBL] [Abstract][Full Text] [Related]
20. [Construction of transmembrane 6 superfamily member 2 E167K gene knock-in mouse model by using CRISPR/Cas9 technology].
Sun BK; Liu SS; Zhang J; Xuan SY; Xin YN
Zhonghua Gan Zang Bing Za Zhi; 2020 Jul; 28(7):591-596. PubMed ID: 32791795
[No Abstract] [Full Text] [Related]
[Next] [New Search]
